Drugs / ADI-SS PEG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00029900 | Sep 2001 → Aug 2003 | melanoma, metastatic neoplasm | FDA Office of Orphan Products Development | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADI-SS PEG | “In this study, patients each receive 3 intramuscular treatments of ADI-SS PEG over a 4-week period.” NCT00029900 ↗ |
| Modality | Protein / enzyme biologic | “the arginine-degrading enzyme arginine deiminase (ADI) coupled to polyethylene glycol (PEG)” NCT00029900 ↗ |
| Route | Intramuscular | “3 intramuscular treatments of ADI-SS PEG” NCT00029900 ↗ |